Three targeted drugs as first treatment for aggressive B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new combination of three targeted drugs as the first treatment for aggressive B-cell lymphomas. The goal is to see if this approach can effectively treat the lymphoma and reduce the need for standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have a confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL) or a similar aggressive B-cell lymphoma
- You must not have had prior chemotherapy for lymphoma, except for a short emergency course or steroid treatment
- Your cancer must show activity on a PET-CT scan
- You need adequate kidney, liver, and blood counts (some allowance for lymphoma-related changes)
- You must not have lymphoma in the brain or spinal cord
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs, polatuzumab vedotin and glofitamab, for people with large B-cell lymphoma that came back or didn't go away after their first standard treatment. The goal is to see if this combination can help control the lymphoma.
This study tests a combination of three newer targeted drugs for older adults (70+) who have just been diagnosed with diffuse large B-cell lymphoma and have not yet received any treatment. The goal is to see if this drug combo can control the lymphoma effectively while being manageable for older patients.
This study tests a combination of three drugs—pola, zanubrutinib, and lenalidomide plus prednisone—for people newly diagnosed with diffuse large B-cell lymphoma. The goal is to see if this treatment can control the disease and improve outcomes.
This Phase 2 study tests two medicines—glofitamab and polatuzumab—together with chemotherapy to treat newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL) that has the CD20 marker. It aims to improve how well the lymphoma responds and how long responses last.
This trial tests whether combining a short course of radiation with a targeted antibody drug (glofitamab) can help people with aggressive large B-cell lymphoma that came back after treatment, especially if they have bulky tumors. It aims to find a new option for hard-to-treat cases.
This trial tests a combination of three drugs (mosunetuzumab, polatuzumab vedotin, and lenalidomide) for people with diffuse large B-cell lymphoma (a type of blood cancer) that has come back or not responded to previous treatment. The goal is to see if this combination is safe and effective.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.